ArticleInternational journal of hematology2012

Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.

Miki Kiyota et al.PubMed ↗Publisher ↗

No numbers read from the abstract.